Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.

@article{Patick1997ActivitiesOT,
  title={Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.},
  author={Amy K. Patick and Theodore J. Boritzki and Laura A Bloom},
  journal={Antimicrobial agents and chemotherapy},
  year={1997},
  volume={41 10},
  pages={2159-64}
}
Nelfinavir mesylate (formerly AG1343) is a potent and selective, nonpeptidic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that was discovered by protein structure-based design methodologies. We evaluated the antiviral and cytotoxic effects of two-drug combinations of nelfinavir with the clinically approved antiretroviral therapeutics zidovudine (ZDV), lamivudine (3TC), dideoxycytidine (ddC; zalcitabine), stavudine (d4T), didanosine (ddI), indinavir, saquinavir, and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV1 patients, abstr. 371

  • S. Kravcik, J. Sahai, +8 authors W. Cameron
  • In Abstracts of the 4th Conference on…
  • 1997
1 Excerpt

Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV1 children, abstr

  • P Krogstad, B. Kerr, +4 authors Y. Bryson
  • Abstracts of the 4th Conference on Retroviruses…
  • 1997
1 Excerpt

The efficacy of VIRACEPTt (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC, abstr

  • W. Powderly, M. Sension, M. Conant, A. Stein, N. Clendeninn
  • Abstracts of the 4th Conference on Retroviruses…
  • 1997
1 Excerpt

A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPTt as monotherapy in HIV positive patients, abstr. Tu.B.2129

  • M. Conant, M. Markowitz, A. Hurley, D. Ho, J. Peterkin, S. Chapman
  • In Abstracts of the XI International Conference…
  • 1996
1 Excerpt

A randomized phase II study of VIRACEPTt, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, abstr. Mo.B.413

  • K. Henry, A. Lamarca, R. Myers, S. Chapman
  • In Abstracts of the XI International Conference…
  • 1996

Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir

  • A. K. Patick, M. Duran, Y. Cao, T. Ho, Z. Pei, M. R. Keller
  • Antiviral Ther
  • 1996
3 Excerpts

Similar Papers

Loading similar papers…